Pinellas County forensic lab named one of top 14 in U.S.
ASCLD ranked the forensic lab among the best in the nation based on its efficiency in expediting court cases and supporting criminal convictions and exonerations. The lab is credited with ensuring the highest levels of quality analysis.
The Pinellas County lab was the only Florida-based forensics lab to receive the society's Foresight Maximus Award, which is granted only to labs that perform at a standard of 90 percent efficiency in relation to the speed and cost of service for taxpayers.
Out of 220 nationwide submissions, only 14 laboratories received this distinction.
The forensic lab is operated by the Pinellas County Medical Examiner and is fully funded by the county's Board of Commissioners. The lab has provided crucial forensic analysis in cases involving DNA, seized drugs, fire debris and toxicology for the criminal justice community.
For more information on the highly regarded lab, go here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
How Myeloma Plays Hide and Seek With CAR T Cells
TOPLINE: G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) occurs through biallelic genetic inactivation and hypermethylation-driven epigenetic silencing. Among 10 patients who relapsed, eight showed GPRC5D loss, while two had mixed expression. METHODOLOGY: Researchers conducted whole-genome sequencing (WGS) and whole-genome bisulfite sequencing (WGBS) analysis on MM samples from 10 patients who relapsed after GPRC5D CAR T-cell therapy. Analysis included CD138+ MM cells isolated from bone marrow samples with purity exceeding 80%, with tumor samples sequenced at 100× coverage and matched normal samples at 30× coverage. Investigators performed targeted bisulfite sequencing to evaluate methylation status of GPRC5D regulatory regions across seven MM cell lines, with library construction and sequencing conducted by specialized institutes. Patient characteristics included median age of 57.5 years (range, 44-66 years), equal gender distribution, and 90% having high-risk cytogenetic abnormalities. TAKEAWAY: Genetic alterations were identified in three cases: one with homozygous deletion in GPRC5D gene, another with biallelic loss in regulatory regions, and a third with homozygous deletions in both TNFRSF17 and GPRC5D after sequential anti-B-cell maturation antigen and anti-GPRC5D CAR T-cell therapies. Multiple hypermethylation sites were present in transcriptional regulatory elements of GPRC5D gene in five posttreatment MM samples, with no genetic changes detected at GPRC5D locus in seven cases. GPRC5D expression showed inverse correlation with methylation levels in regulatory regions of MM cell lines, with azacitidine treatment inducing GPRC5D messenger RNA and protein expression in hypermethylated MM cell lines. All 10 patients achieved complete response or better as best response with median time to best response of 2.5 months (range, 0.5-15.3 months), though median time to disease progression was 15.9 months (range, 3.0-26.5 months). IN PRACTICE: 'Our findings highlight that biallelic genetic inactivation and hypermethylation-driven epigenetic silencing are key mechanisms contributing to GPRC5D loss and treatment resistance,' wrote the authors of the study. SOURCE: The study was led by Mingshan Niu, Blood Diseases Institute, Xuzhou Medical University in Xuzhou, China. It was published online in Blood. LIMITATIONS: According to the authors, the structural variant deletions on chromosomes may be missed by 100× WGS in patients with a clone size less than 20%. The limit of detection for quantitative polymerase chain reaction ranged from 16 to 50 copies per reaction, indicating sensitivity limitations of these detection methods. Additionally, genetic alterations in the GPRC5D locus could either be acquired after CAR T-cell therapy or selected from preexisting clones, necessitating more sensitive detection methods for dynamic monitoring. DISCLOSURES: The research received support from the National Natural Science Foundation of China (82270181) and the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (21KJA320005). The authors reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
4 hours ago
- Medscape
Behavioral Therapy as First-Line for Bladder Control in PD?
TOPLINE: Structured behavioral therapy focused on pelvic floor muscle exercise was noninferior to treatment with solifenacin for alleviating overactive bladder symptoms in patients with Parkinson's disease (PD), new research showed. Because it was also associated with fewer side effects, especially falls, researchers recommended the behavioral therapy as a first-line treatment option. METHODOLOGY: This 12-week randomized noninferiority trial was conducted between 2018 and 2023 within four Veterans Affairs healthcare systems in the US. Overall, 77 patients diagnosed with PD and overactive bladder symptoms, as measured with an International Consultation on Incontinence Questionnaire overactive bladder module (ICIQ-OAB) symptom score ≥ 7, were included. All participants (mean age, 71 years; 84% men; 90% White individuals) were randomly assigned to receive either pelvic floor muscle exercise-based behavioral therapy with urge suppression training (n = 36) or 5 mg solifenacin daily with need-based titration up to 10 mg daily (n = 41). The primary outcome was ICIQ-OAB symptom score at 12 weeks. Secondary outcomes were ICIQ-OAB bother and quality of life scores and drug-related adverse events. TAKEAWAY: At 12 weeks, clinically significant improvement in ICIQ-OAB scores was observed across both treatment groups within a noninferiority margin of 15% (drug vs behavioral therapy: mean ICIQ-OAB score, 5.8 vs 5.5; P = .02). Both groups also had a reduction in symptom frequency, which was associated with a reduction in bother scores and an improvement in overactive bladder-related quality of life. Compared with the behavioral therapy group, the solifenacin group had a greater number of adverse events, including dry mouth (P = .002) and pain or burning during urination (P = .03). They also had a greater number of falls (6 vs 0). IN PRACTICE: 'The finding of increased falls in the solifenacin therapy group reinforces the need to carefully consider the risk-benefit ratio of medications for urinary symptoms, especially given the increased risk of falls among persons with PD. Results of this study suggest that behavioral therapy is an effective treatment option for persons with PD,' the investigators wrote. SOURCE: The study was led by Camille P. Vaughan, MD, Division of Geriatrics and Gerontology in the Department of Medicine, Emory University, Atlanta. It was published online on July 14 in JAMA Neurology. LIMITATIONS: The follow-up duration was limited to 12 weeks, restricting insight into longer-term outcomes. The cohort predominantly had male participants, reducing the generalizability of the findings, and the study relied on patient-reported data. Additionally, a higher dropout in the drug group led to nonrandom missing data, potentially biasing comparisons. DISCLOSURES: The study was funded by a grant from Veterans Affairs Rehabilitation Research and Development. Two investigators reported receiving grants from various sources during the conduct of the study. The other nine investigators reported having no relevant financial relationships. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
7 hours ago
- Yahoo
SpaceX launch photos: Falcon 9 launches SES O3b mPOWER satellites from Cape Canaveral, Florida
After a waning-second scrub the previous day, SpaceX successfully launched a pair of SES O3b mPOWER satellites into medium-Earth orbit on Tuesday, July 22, from Cape Canaveral Space Force Station. The Falcon 9 lifted off at 5:12 p.m. After soaring skyward due east, the rocket's first-stage booster landed aboard SpaceX's drone ship Just Read the Instructions in the Atlantic Ocean. The Space Force's 45th Weather Squadron had only predicted a paltry 20% chance of "go for launch" weather, citing cumulus clouds, lightning and surface electric fields. Cape Canaveral: Is there a launch today? Upcoming SpaceX, NASA, ULA rocket launch schedule at Cape Canaveral For the latest news from Cape Canaveral Space Force Station and NASA's Kennedy Space Center, visit Another easy way: Click here to sign up for our weekly Space newsletter. Rick Neale is a Space Reporter at FLORIDA TODAY. Contact Neale at Rneale@ Twitter/X: @RickNeale1 Space is important to us and that's why we're working to bring you top coverage of the industry and Florida launches. Journalism like this takes time and resources. Please support it with a subscription here. This article originally appeared on Florida Today: SpaceX launch photos: Falcon 9 rocket launches SES mPOWER satellites Solve the daily Crossword
